Summary
Melphalan absorption was studied over three consecutive days in five patients with multiple myeloma. On 1 day melphalan (approximately 7 mg/m2=10–12 mg) was administered IV, on 1 day PO fasting, and on 1 day PO after a standard breakfast. The order was different for each patient to minimise trends that might affect absorption. Melphalan concentrations were determined by high-pressure liquid chromatography and fitted to biexponential equations by computer. The parameters of these equations were in broad agreement with previously published data, and melphalan absorption varied between patients. Considerable differences were observed in the melphalan concentration curves between the ‘PO fed’ and ‘PO fasting’ days: on the PO fed days the delay before absorption started was longer (1.1±0.5 h as against 0.3±0.1 h); peak plasma levels were one-third the value (65±15 ng/ml; 195±80 ng/ml) and occured at twice the time after administration (2.8±0.8 h; 1.3±0.3 h); and areas under the curve were smaller 10.8±4.7 min x μg/ml; 23.8±13.8 min x μg/ml). There was a significant difference between the fraction of the dose of melphalan absorbed on the PO fed day (0.49±0.20) and on the PO fasting day (0.93±0.22), with P0.005. This work suggests that melphalan should be taken first thing in the morning to obtain greatest absorption.
Similar content being viewed by others
References
Alberts DS, Chang SY, Chen H-SG, Moon TE, Evans TL, Furner RL, Himmelstein K, Gross JF (1979a) Kinetics of intravenous melphalan. Clin Pharmacol Ther 26:73
Alberts DS, Chang SY, Chen H-SG, Evans TL, Moon TE (1979b) Oral melphalan kinetics. Clin Pharmacol Ther 26:737
Bosanquet AG, Gilby ED (1982a) Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 18:355
Bosanquet AG, Gilby ED (1982b) Measurement of plasma melphalan at therapeutic concentrations using isocratic high-performance liquid chromatography. J Chromatogr 232:345
Bosanquet AG, Bird MC, Price WJP, Gilby ED (1983a) An assessment of a short-term chemosensitivity assay in chronic lymphocytic leukaemia. Br J Cancer 47:781
Bosanquet AG, Bird MC, Gilby ED (1983b) Short term tumor chemosensitivity assay for haematological cancers: Improved leucocyte identification and comparison of drug sensitivities in blood, marrow and lymph node: In: 13th International Congress of Chemotherapy, Vienna, 28th Aug, to 2nd Sept. 1983, Proceedings. Spitzy KH, Karrer K (eds). VH Egermann, Vienna, Part 224, p 130
Brox L, Birkett L, Belch A (1979) Pharmacology of intravenous melphalan in patients with multiple myeloma. Cancer Treat Rev [Suppl] 6:27
Chang SY, Alberts DS, Melnick LR, Walson PD, Salmon SE (1978) High-pressure liquid chromatographic analysis of melphalan in plasma. J Pharm Sci 67:679
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31
McElwain TJ, Hedley DW, Burton G, Clink HM, Gordon MY, Jarman M, Juttner CA, Millar JL, Milstead RAV, Prentice G, Smith IE, Spence D, Woods M (1979) Bone marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high dose melphalan. Br J Cancer 40:72
Metzler CM (1969) NONLIN: a computer program for parameter estimation in nonlinear situations. Upjohn Co., Kalamazoo (Technical Report 7292/69/7292/005)
Pallante SL, Fenselau C, Mennel RG, Brundrett RB, Appler M, Rosenshein NB, Colvin M (1980) Quantitation by gas chromatography-chemical ionisation mass spectrometry of phenylalanine mustard in plasma of patients. Cancer Res 40:2268
Pinkerton CR, Welshmam SG, Glasgow JFT, Bridges JM (1980) Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia? Lancet 2:944
Simpson HW, Stoney PJ (1977) A circadian variation of melphalan (l-phenylalanine nitrogen mustard) toxicity to murine bone marrow: relevance to cancer treatment protocols. Br J Haematol 35:459
Taha A-K, Ahmad RA, Gray H, Roberts CI, Rogers HJ (1982) Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma. Cancer Chemother Pharmacol 9:57
Tattersall MHN, Jarman M, Newlands ES, Holyhead L, Milstead RAV, Weinberg A (1978) Pharmacokinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur J Cancer 14:507
Woodhouse KW, Hamilton P, Lennard A, Rawlins MD (1983) The pharmacolinetics of melphalan in patients with multiple myeloma: An intravenous/oral study using a conventional dose regimen. Eur J Clin Pharmacol 24:283
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bosanquet, A.G., Gilby, E.D. Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma. Cancer Chemother. Pharmacol. 12, 183–186 (1984). https://doi.org/10.1007/BF00256542
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00256542